Alnylam Pharmaceuticals (ANLY) Bullish Stance Reiterated at Needham & Company Post Q1

May 9, 2014 8:30 AM

Needham & Company analyst Alan Carr reiterated a Buy rating and $94 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found